We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

86 hedge funds and large institutions have $332M invested in CytomX Therapeutics in 2017 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

800% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 3

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

79% more capital invested

Capital invested by funds: $185M → $332M (+$146M)

45% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 20

26% more funds holding

Funds holding: 68 → 86 (+18)

6.08% more ownership

Funds ownership: 46.31% → 52.39% (+6.1%)

Holders
86
Holders Change
+18
Holders Change %
+26.47%
% of All Funds
2.14%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.1%
New
27
Increased
29
Reduced
20
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$16.4M
2
BlackRock
BlackRock
New York
+$13.2M
3
EC
EcoR1 Capital
California
+$10.5M
4
PA
Perceptive Advisors
New York
+$7.99M
5
DCM
Driehaus Capital Management
Illinois
+$3.88M

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$17M
2
VMI
VHCP Management II
New York
-$3.8M
3
TCM
Tekla Capital Management
Massachusetts
-$2.97M
4
CAM
Cormorant Asset Management
Massachusetts
-$1.86M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$696K
Name Holding Trade Value Shares
Change 		Change in
Stake
HP
51
Harbourvest Partners
Massachusetts
$432K +$197K +15,000 +150%
VKH
52
Virtu KCG Holdings
New York
$388K +$296K +22,465 New
Wells Fargo
53
Wells Fargo
California
$387K +$102K +7,747 +53%
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$378K +$11.5K +872 +4%
Russell Investments Group
55
Russell Investments Group
United Kingdom
$377K – – –
HLA
56
Hamilton Lane Advisors
Pennsylvania
$366K +$279K +21,199 New
New York State Common Retirement Fund
57
New York State Common Retirement Fund
New York
$361K +$13 +1 +0%
Citadel Advisors
58
Citadel Advisors
Florida
$313K +$238K +18,116 New
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$297K – – –
Manulife (Manufacturers Life Insurance)
60
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$296K +$23.3K +1,768 +11%
MF
61
Magnetar Financial
Illinois
$255K +$194K +14,773 New
TC
62
TFS Capital
Pennsylvania
$247K +$188K +14,307 New
Two Sigma Investments
63
Two Sigma Investments
New York
$238K +$181K +13,762 New
Barclays
64
Barclays
United Kingdom
$221K +$166K +12,591 +5,498%
AIG
65
American International Group
New York
$217K +$11K +834 +7%
SO
66
STRS Ohio
Ohio
$207K +$158K +12,000 New
DTL
67
Dynamic Technology Lab
Singapore
$206K +$157K +11,956 New
NFA
68
Nationwide Fund Advisors
Ohio
$203K -$15.6K -1,182 -9%
Goldman Sachs
69
Goldman Sachs
New York
$190K +$145K +10,982 New
ARTA
70
A.R.T. Advisors
New York
$179K +$137K +10,400 New
HIM
71
Hillsdale Investment Management
Ontario, Canada
$159K +$121K +9,200 New
Legal & General Group
72
Legal & General Group
United Kingdom
$86K -$3.25K -247 -5%
MCM
73
Manchester Capital Management
Vermont
$56K – – –
UBS Group
74
UBS Group
Switzerland
$53K -$13.4K -1,018 -25%
DADC
75
D.A. Davidson & Co
Montana
$43K +$32.9K +2,500 New
1 2
3
4

CTMX Hedge Fund Activity: Q1 2017 in Review

86 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q1 2017, worth a combined $332M — up 79% from $185M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CTMX positions and 3 closed out — a net gain of 24 holders — while 29 added to existing stakes and 20 trimmed.

The largest buyer was BVF Inc, adding an estimated $16.4M. The largest seller was Putnam Investments, cutting an estimated $17M.

  • 86 institutional investors held CytomX Therapeutics (CTMX) as of Q1 2017, up from 68 in Q4 2016.
  • Funds reported $332M of CytomX Therapeutics stock for Q1 2017, up 79% quarter-over-quarter.
  • 27 funds opened new CytomX Therapeutics positions in Q1 2017 and 3 closed out, a net change of +24 holders.
  • The largest CytomX Therapeutics buyer in Q1 2017 was BVF Inc, an estimated $16.4M added.
  • The largest CytomX Therapeutics seller in Q1 2017 was Putnam Investments, an estimated $17M sold.

Based on aggregated 13F filings for Q1 2017.